We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Assay May Boost Treatment of Non-Hodgkin Lymphoma

By LabMedica International staff writers
Posted on 14 Nov 2017
Print article
Image: The Hitachi ABI 3130XL capillary electrophoresis genetic analyzer system (Photo courtesy of Cal-L enterprises).
Image: The Hitachi ABI 3130XL capillary electrophoresis genetic analyzer system (Photo courtesy of Cal-L enterprises).
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide. Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype.

DLBCL includes three major subtypes termed germinal center B-cell-like, activated B-cell-like, and primary mediastinal B-cell lymphoma. A reliable, accessible, rapid, and cost-effective new gene expression signature assay has been developed that can enhance lymphoma management by helping to match tumors with the appropriate targeted therapy.

A team of scientists working with those at the Centre Henri Becquerel (Rouen, France) collected a total of 218 biopsy samples, including fresh/frozen biopsies of 150 DLBCL cases had previously been analyzed using U133 + 2 GEP arrays. A total of 38 primary mediastinal B-cell lymphoma (PMBL) cases from another trial and 29 from the Center Henri Becquerel, were also included as well as 30 DLBCL cases from the same institution.

The investigators extracted RNA samples from formalin-fixed paraffin-embedded (FFPE) tissue using Siemens TPS and Versant reagents kit. Immunoperoxidase stains were performed on a Benchmark Ultra automated stainer using Ultraview Universal diaminobenzidine detection kits. A rapid and inexpensive reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay was developed that allows for an accurate classification of germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCLs. The resulting MLPA amplicons were analyzed by fragment analysis using an ABI 3130 XL capillary electrophoresis system.

The team tested 150 RNA samples extracted from biopsies and 42% of the samples had the ABC subtype, 37% the GCB subtype, and 10% molecular PMBL, while 11% of samples could not be classified. Overall, the RT-MLPA assay correctly assigned 85.0% of the cases into the expected subtypes compared to 78.8% with immunohistochemistry. The assay was also able to detect the MYD88 L265P mutation, one of the most common genetic abnormalities found in ABC DLBCLs. This information can influence treatment, since the presence of the mutation has been suggested to be predictive of ibrutinib sensitivity.

The authors concluded that RT-MLPA appears as an efficient, rapid, and cost-effective alternative to the current methods used in the clinic to establish the cell of origin classification of DLBCLs. In contrast to other technologic approaches its implementation requires only common laboratory equipment, that is, a thermal cycler and a capillary genetic analyzer, and does not necessitate the acquisition of any specialized platform. By allowing the identification of the three major DLBCL subtypes and a simultaneous evaluation of multiple prognostic and theranostic markers and therapeutic targets, RT-MLPA could contribute to a more efficient management of these aggressive tumors in both clinical trials and daily practice. The study was published in the November 2017 issue of the Journal of Molecular Diagnostics.

Related Links:
Centre Henri Becquerel

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.